Shots:
- Zealand Pharma & Roche will develop & market petrelintide & its products incl. petrelintide + CT-388 (Roche’s asset) in the US & EU for weight loss, with Roche obtaining exclusive marketing rights in the rest of the world
- Zealand will handle ~50% marketing in the US & EU with opt-in/out rights under specific conditions, while Roche will manage commercial manufacturing & supply
- As per the deal, Zealand will get $1.65B upfront ($1.4B at closing + $250M over 2yrs.), ~$1.2B upon start of P-III trials, & ~$2.4B in sales-based milestones, plus tiered royalties, while Roche will get $350M for CT-388 as the 1st combination. Companies will share 50/50 US & EU profits/losses for monotx. & combo products
Ref: Roche | Image: Roche & Zealand Pharma
Related News:- Roche Reports the P-IIb (PADOVA) Trial Data of Prasinezumab for Early-Stage Parkinson’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
